Shane Olwill - Aug 30, 2021 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PIRS)

Role
Chief Development Officer
Signature
/s/ Megan Gates, Attorney-in-Fact
Stock symbol
PIRS
Transactions as of
Aug 30, 2021
Transactions value $
-$138,012
Form type
4
Date filed
9/1/2021, 04:38 PM
Previous filing
Aug 3, 2021
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PIRS Common Stock Options Exercise $58.4K +38.4K +827.94% $1.52* 43K Aug 30, 2021 Direct
transaction PIRS Common Stock Sale -$46K -9.2K -21.38% $5.00* 33.8K Aug 30, 2021 Direct
transaction PIRS Common Stock Sale -$150K -29.2K -86.29% $5.15* 4.64K Aug 30, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PIRS Stock Option (right to buy) Options Exercise $0 -38.4K -38.4% $0.00 61.6K Aug 30, 2021 Common Stock 100K $1.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 to $5.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 The option has fully vested.